Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang - LARVOL DELTA

EFFICACY AND SAFETY OF ADJUVANT THERAPY WITH REBAMIPIDE IN HELICOBACTER PYLORI INFECTION: RESULTS FROM THE EUROPEAN REGISTRY ON H. PYLORI MANAGEMENT (HP-EUREG) (UEGW 2026) - "In real-world Russian clinical practice, the addition of rebamipide to the standard triple therapy with amoxicillin-clarithromycin and bismuth quadruple therapy with amoxicillin-clarithromycin significantly increased treatment effectiveness without affecting patient compliance. However, tolerability was poorer with rebamipide, suggesting that its use should be adapted to individual patient characteristics and clinical circumstances."

Clinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease

GASTRIC MUCOSAL CHANGES DURING LONG-TERM REBAMIPIDE THERAPY IN PATIENTS WITH TYPE 1 GASTRIC NEUROENDOCRINE TUMORS AND AUTOIMMUNE GASTRITIS (UEGW 2026) - "Long-term rebamipide therapy (>24 months) is associated with regression of atrophy and neuroendocrine cell hyperplasia in patients with type 1 g‑NETs and AIG. The regression of neuroendocrine cell hyperplasia opens the possibility for pharmacological intervention at the preclinical stage. These findings support the inclusion of long‑term gastroprotective therapy in the comprehensive management of this patient group."

Clinical • Gastrointestinal Disorder • Immunology • Neuroendocrine Tumor • Oncology • Solid Tumor

PREVENTIVE AND THERAPEUTIC EFFECT OF REBAMIPIDE IN NSAID-INDUCED GASTROENTEROPATHIES (UEGW 2026) - "No significant differences were found when comparing rebamipide and PPIs (omeprazole or lansoprazole). In the study by Naito Y et al., it was shown that rebamipide is not inferior in efficacy to famotidine, however, in the study by Yamao J-I et al., famotidine was found to be more effective than rebamipide. our meta-analysis proved the efficacy and safety of rebamipide in the prevention and treatment of gastrointestinal injuries caused by the use of NSAIDs, which was also confirmed by previous meta-analyses and certain recommendations and consensus of various communities of specialists dealing with this problem. Rebamipide has a therapeutic effect in all NSAID-associated gastrointestinal injuries"

Gastrointestinal Disorder • HRH2

The evaluation of supportive care for stomatitis in patients with recurrent/ relapsed Müllerian carcinoma received chemotherapy of pegylated liposomal doxorubicin (clinicaltrials.gov) - P=N/A | N=42 | Completed | Sponsor: Japan Doxil study group | Unknown status ➔ Completed

Trial completion • Dental Disorders • Oncology • Stomatitis

Pharmacologic Management of Post Gastric Endoscopic Submucosal Dissection Ulcers: An Arm-Based Network Meta-Analysis of Randomized Controlled Trials (ACG 2026) - "Rebamipide 100 mg had the highest probability of being ranked the most effective treatment (37%), followed by roxatidine 75 mg (36%)... Twenty-six RCTs involving 3,396 patients were included. For the primary outcome of ulcer healing at 8 weeks, 1,954 patients across 16 treatment regimens were analyzed (Figure 2A). The league table demonstrated no statistically significant differences in healing rates among the evaluated interventions."

Retrospective data

Comparative Efficacy of Rebamipide, Pantoprazole, and Their Combination for Gastroprotection in Patients with Atrial Fibrillation Receiving Direct Oral Anticoagulants: The Randomized REGATA Study. (PubMed, Med Sci (Basel)) - "Concurrently, fecal zonulin levels, reflecting intestinal epithelial permeability, fell by 45.1% in the rebamipide arm (from 434 to 225 ng/mL; p < 0.001) and by 47.1% in the P + R arm (from 347 to 182 ng/mL; p < 0.001) compared to a minimal 3.0% fluctuation in the pantoprazole group. While demonstrating non-inferiority regarding primary clinical endpoints, both rebamipide monotherapy and combination (P + R) therapy achieved some advantages over pantoprazole monotherapy in decreasing subclinical GI inflammation and restoring intestinal epithelial barrier integrity."

Clinical • Journal • Atrial Fibrillation • Cardiovascular • Dyspepsia • Gastrointestinal Disorder • Inflammation

Transcriptomic analysis of rebamipide-induced gene expression changes toward anti-inflammatory profiles in human conjunctival fibroblasts. (PubMed, Biochem Biophys Res Commun) - "Rebamipide modulates the gene expression profile of HCFCs toward an anti-inflammatory and anti-fibrotic state, primarily through the downregulation of CSF3 and associated pro-inflammatory cytokines. These findings suggest Rebamipide's potential as a novel topical therapeutic strategy for reducing postoperative scarring and complications in transconjunctival surgery."

Journal • Dry Eye Disease • Fibrosis • Ophthalmology • CCL2 • CDKN1A • CSF3 • CXCL6 • IL1B • IL6 • TP53

Efficacy and safety of H. pylori eradication therapy in real-world clinical practice: results of the «PAMIR» observational program (PubMed, Ter Arkh) - "The effectiveness of H. pylori eradication with a ready-to-use set of capsules and tablets for standard triple therapy is ensured by high patient compliance. The combination of standard triple therapy with bismuth, probiotics, and/or rebamipide increases treatment efficacy."

Journal • Observational data • Real-world evidence • Infectious Disease • Pain • Peptic Ulcer

Clinical Study Comparing Diosmin vs Rebamipide as Adjuvant Therapies vs Conventional Therapy in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - P2 | N=66 | Recruiting | Sponsor: Tanta University

New P2 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

A 15-Year-Old Man Presented with Abdominal Pain (AOCC-IMKASID 2026) - "A diagnosis of eosinophilic esophagitis and eosinophilic enteritis with early small-bowel Crohn's disease (r/o) was established, and a four-week course of partial enteral nutrition (PEN) combined with a two-food elimination diet was initiated alongside a proton pump inhibitor, rebamipide, and probiotics...The patient was managed with bowel rest, peripheral parenteral nutrition, intravenous piperacillin-tazobactam and metronidazole, followed by six weeks of exclusive enteral nutrition (EEN) and concurrent initiation of methotrexate (MTX)...Infliximab (IFX) combined with azathioprine (AZA 25 mg/day) was initiated, yielding clinical remission (PCDAI 5) by May 2026, with endoscopic improvement confirmed on follow-up colonoscopy...This case demonstrates that stepwise therapy— EEN, CDED, and escalation to infliximab—achieves clinical and endoscopic remission even in severe pCD with microperforation. Concurrent MASLD warrants proactive hepatotoxicity monitoring with MTX,..."

Crohn's disease • Dyspepsia • Eosinophilic Esophagitis • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Hepatology • Immunology • Inflammatory Bowel Disease • Metabolic Dysfunction-Associated Steatotic Liver Disease • Obesity • Pain • CD27

Inhibition of STAT6 Signaling by Rebamipide Attenuates IL-4- and IL-13-Induced Eotaxin Expression in Corneal Fibroblasts. (PubMed, Exp Eye Res) - "These findings demonstrate that IL-4- or IL-13-stimulated eotaxin production in human corneal fibroblasts is mediated through the STAT6 signaling pathway. Rebamipide inhibited STAT6 activation, leading to reduced eotaxin production, suggesting that its therapeutic effect in VKC is due to the suppression of STAT6-mediated eotaxin production, which may reduce eosinophil accumulation to the cornea."

Journal • Conjunctivitis • Corneal Abrasion • Dry Eye Disease • Inflammation • Ocular Infections • Ocular Inflammation • Ophthalmology • CCL11 • IL13 • IL4 • STAT6

Mucin armoured diethylaminoethyl-dextran cloaked rebamipide based oral nanoformulation for the therapy of inflammatory bowel disease. (PubMed, Mater Today Bio) - "The trapped rebamipide inhibits the production of pro-inflammatory mediators and promotes the production of mucin 2 (Muc2) protein, which promotes colon mucosal regeneration and goblet cell viability. Based on the necessity of controlling drug release and regulation of drug action for complete IBD treatment, we believe that the M@D@Re-SCNPs are a promising drug delivery system for UC treatment."

Journal • Gastroenterology • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Bowel Disease • Ulcerative Colitis • MUC2

Exploring the Active Components and Mechanisms of Schisandra Chinensis for Treatment of Non-small Cell Lung Cancer Based on Network Pharmacology and Experimental Validation. (PubMed, Recent Pat Anticancer Drug Discov) - "Gomisin R exerts anti-NSCLC effects, in part, by regulating PTGS2 expression, leading to suppression of cell proliferation, attenuation of oxidative stress and inflammatory responses, and induction of apoptosis in A549 cells. This study provides quantitative evidence supporting Gomisin R as a key active component of Schisandra chinensis for the treatment of NSCLC."

IO biomarker • Journal • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BCL2 • CASP9 • IL1B • IL6 • PACERR • PTGS2

Response to Valdovinos-Díaz et al., regarding «Rebamipide as adjuvant therapy in Helicobacter pylori eradication regimens». (PubMed, Rev Gastroenterol Mex (Engl Ed)) - No abstract available

Journal • Infectious Disease

Drug Repurposing of Rebamipide to Manage Immunotherapy-Induced Mucosal Toxicities: A Case Report (MASCC-ISOO 2026) - "Methods We present a case of a 50-year-old woman with early-stage triple-negative breast cancer completed neoadjuvant chemoimmunotherapy, surgery, adjuvant radiotherapy, and one year of pembrolizumab. Conclusions This case demonstrates the potential efficacy of a novel dispersible rebamipide formulation in managing immunotherapy-induced oral mucositis and esophagitis. The rapid and complete symptom resolution supports its mucosal protective role and serves as a proof of concept for conducting larger prospective clinical trials to validate its therapeutic benefits in this setting."

Case report • Clinical • Breast Cancer • Gastrointestinal Disorder • Mucositis • Solid Tumor • Stomatitis • Triple Negative Breast Cancer

Rebamipide as adjuvant therapy in Helicobacter pylori eradication regimens. (PubMed, Rev Gastroenterol Mex (Engl Ed)) - No abstract available

Journal • Infectious Disease

Rebamipide attenuates LPS-induced acute lung injury in rats via modulation of macrophage polarization, PDE4B/cAMP/PKA/p-CREB and NF-κB signaling. (PubMed, J Mol Histol) - "In conclusion, REB exerts protective effects against LPS-induced ALI through modulation of inflammatory and oxidative stress pathways involving the PDE4B/cAMP/PKA/p-CREB axis and NF-κB signaling. These findings suggest that REB may represent a promising candidate for further investigation in inflammatory lung disorders."

Journal • Preclinical • Acute Lung Injury • Inflammation • Pulmonary Disease • Respiratory Diseases

Synergistic gastric retention of rebamipide via hollow bioadhesive microspheres for enhanced ulcer therapy. (PubMed, Colloids Surf B Biointerfaces) - "In an ethanol-induced gastric ulcer rat model, the system effectively reduced ulcer indices by prolonging local drug exposure, and showed comprehensive therapeutic effects, including anti-inflammatory, antioxidant, and enhanced mucosal defense activities, with no observed significant toxicity. This study provides an effective and safe drug delivery strategy for the local and sustained treatment of gastric ulcers."

Journal • Peptic Ulcer

Structure-based E-pharmacophore guided in silico repurposing of clinically approved drugs targeting methionyl-tRNA synthetase against leishmaniasis. (PubMed, J Mol Graph Model) - "The virtual screening identified four promising hits: Bofutrelvir, Rebamipide, Selumitinib, and Carvedilol...These findings provide a strong foundation for drug repurposing and highlight these compounds as potential anti-leishmanial agents. Further biological validation is warranted to validate their anti-leishmanial efficacy."

Journal • Infectious Disease

Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation. (PubMed, Pharmaceuticals (Basel)) - " These findings demonstrate Rebamipide's dual-phase, multi-targeted mechanism: early protection against diet-induced metabolic injury and robust reversal of established MASLD pathology. The identified protein triad (Mttp, Cyp2c6, Hspa9) and associated pathways provide novel biomarker candidates and mechanistic insight supporting Rebamipide's repurposing as a therapeutic for metabolic liver disease."

Journal • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatohepatitis • Metabolic Dysfunction-Associated Steatotic Liver Disease • HSPA9

GERD Symptoms Do Not Worsen During Neoadjuvant Chemotherapy but Increase After Radiotherapy in Breast Cancer Patients (GBCC 2026) - "During chemotherapy, patients were randomly assigned to one of three gastric medications: esomeprazole (proton pump inhibitor), tegoprazan (potassium- competitive acid blocker), or rebamipide (gastric mucosal protective agent)... GERD-Q scores did not change significantly during the chemotherapy phase (V1-V3) among patients with available assessments (n = 38), and no differences were observed according to chemotherapy regimen, including TCHP and PCAC plus pembrolizumab... GERD symptoms did not worsen during neoadjuvant chemotherapy or the immediate Poster Presentation postoperative period but increased after completion of radiotherapy. These findings suggest that GERD symptom aggravation in breast cancer patients may predominantly occur during the later phases of treatment rather than during chemotherapy itself."

Clinical • Breast Cancer • Gastroenterology • Gastroesophageal Reflux Disease • Oncology • Solid Tumor

Use of rebamipide solution as a submucosal injection material to prevent esophageal stricture after endoscopic submucosal dissection: Animal study. (PubMed, Endosc Int Open) - "The rebamipide solution showed no statistically significant benefit in preventing post-ESD stricture. However, given the small sample size of this study, further studies are needed to clarify its potential role."

Journal • Fibrosis • Gastrointestinal Disorder • Immunology • Peptic Ulcer

Simultaneous quantification of lifitegrast and Rebamipide in hydrogel-based contact lenses using spectroscopic method. (PubMed, Int Ophthalmol) - "The validated UV spectrophotometric method provides a novel and practical analytical tool for the simultaneous estimation of Lifitegrast and Rebamipide in therapeutic contact lenses. Its simplicity and reliability support its translational potential for routine quality control and formulation development in ocular drug delivery for DED."

Journal • Dry Eye Disease • Ophthalmology

Ion-sensitive in-situ gel loaded with rebamipide micelles for the treatment of diabetic keratopathy. (PubMed, Colloids Surf B Biointerfaces) - "Safety assessments confirmed good tolerance. Therefore, Reb-NM-ISGs represent a highly promising, safe, and patient-friendly strategy for managing DK, offering a significant advancement over current Reb therapy and providing a valuable reference for diabetic keratopathy research and ocular nanomedicine."

Journal • Corneal Abrasion • Dry Eye Disease • Ophthalmology • IL1B

Rebamipide for Managing Dyspeptic Symptoms During Proton-Pump Inhibitor Washout Before Helicobacter pylori Testing: A Randomized, Double-Blind, Placebo-Controlled Trial. (PubMed, Turk J Gastroenterol) - "The responder rate was higher in the rebamipide group, but the difference did not reach statistical significance. The poten tial benefit of rebamipide as a rescue therapy during the PPI washout period before H. pylori testing warrants further investigation in larger trials.   Cite this article as: Suksai N, Chueansuwan R, Yongsiri S, Witoon R, Juttuporn A. Rebamipide for managing dyspeptic symptoms during proton-pump inhibitor washout before Helicobacter pylori testing: A randomized, double-blind, placebo-controlled trial. Turk J Gastroenterol. 2026;37(2):251-259."

Clinical • Journal • Dyspepsia • Gastrointestinal Disorder • Infectious Disease • Pain